XML 22 R12.htm IDEA: XBRL DOCUMENT v3.19.1
Stockholders' equity
3 Months Ended
Mar. 31, 2019
Federal Home Loan Banks [Abstract]  
Stockholders' equity

6. Stockholders’ equity

(a) Share capital

Aquinox Pharmaceuticals, Inc. is authorized to issue two classes of stock, common and preferred. The total number of shares Aquinox Pharmaceuticals, Inc. is authorized to issue is 55,000,000 shares, comprised of 50,000,000 common stock and 5,000,000 preferred stock both with a par value of $0.000001 per share. As of March 31, 2019 and December 31, 2018, the total number of shares of common stock issued and outstanding was 23,537,368. As of March 31, 2019 and December 31, 2018, no shares of preferred stock were issued or outstanding.

(b) Stock option plan

On January 27, 2014, the Company’s stockholders approved the 2014 Equity Incentive Plan (“2014 Plan”). The 2014 Plan became effective on March 6, 2014. The 2014 Plan is the successor to and continuation of the Joint Canadian Stock Option Plan (the “2006 Plan”). No further grants will be made under the 2006 Plan. The 2014 Plan provides for the grant of stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, performance stock awards, performance cash awards, and other forms of equity awards to employees, directors, and consultants.

As at March 31, 2019, the maximum number of shares of common stock that may be issued under the 2014 Plan was 4,725,552 shares. Additionally, the number of shares of common stock reserved for issuance under the 2014 Plan will automatically increase on January 1 of each year for a period of up to 10 years, beginning on January 1, 2015 and ending on and including January 1, 2024, by 4% of the total number of shares of capital stock outstanding on December 31 of the preceding calendar year, or a lesser number of shares determined by the board of directors.

 

Stock option transactions and the number of stock options outstanding are summarized below:

 

     NUMBER OF
SHARES
     WEIGHTED
AVERAGE
EXERCISE PRICE
     WEIGHTED
AVERAGE
REMAINING
CONTRACTUAL
LIFE

(IN YEARS)
     AGGREGATE
INTRINSIC
VALUE (IN
THOUSANDS)
 

Outstanding at December 31, 2018

     2,897,294      $ 9.04        7.96      $  —    

Options forfeited

     (264,097 )       11.83        
  

 

 

    

 

 

    

 

 

    

 

 

 

Outstanding at March 31, 2019

     2,633,197      $ 8.76        7.85      $ —    
  

 

 

    

 

 

    

 

 

    

 

 

 

Exercisable as of March 31, 2019

     1,081,220      $  11.38        6.11      $ —    

There were no stock options granted or exercised during the three months ended March 31, 2019.

(c) Stock-based compensation

The fair value of stock options granted is estimated using the Black-Scholes option pricing model with the following weighted average assumptions:

 

     THREE MONTHS ENDED
MARCH 31,
 
     2019    2018  

Expected volatility

   N/A      75 % 

Expected dividends

   N/A      0 % 

Expected terms (years)

   N/A      6.00  

Risk free rate

   N/A      2.72 % 

Weighted average grant-date fair value of stock options

   N/A    $ 11.11  

The Company amortizes the fair value of the stock options on a straight-line basis over the applicable requisite service periods of the awards, which is generally the vesting period. Stock-based compensation expense charged to operating expenses was $1.1 million and $1.3 million for the three months ended March 31, 2019 and March 31, 2018, respectively. Total unrecognized compensation cost for all stock-based compensation plans was $6.7 million and $17.0 million as of March 31, 2019 and March 31, 2018, respectively, which is expected to be recognized over a weighted-average period of 2.61 years (March 31, 2018 – 3.31 years)